阿司匹林降低了慢性乙型肝炎的肝癌風險

StephenW

Aspirin reduces risk for HCC in chronic hepatitis B
ADDED TO EMAIL ALERTS

For patients with chronic hepatitis B, aspirin therapy correlated with a reduced risk for hepatocellular carcinoma, according to a presenter at The Liver Meeting Digital Experience.

“Cirrhosis had a significant effect on the association between use of aspirin and the risk of HCC development,” Heejoon Jang, MD, from the department of internal medicine and Liver Research Institute, Seoul National University Hospital, said during his presentation.
Aspirin

For patients with chronic hepatitis B, aspirin therapy correlated with a reduced risk for hepatocellular carcinoma.

Adobe stock

Using the Korean National Health insurance database, Jang and colleagues identified 329,635 adult patients with chronic hepatitis B; 20,200 of whom received aspirin for 90 or more consecutive days and 309,435 who never received antiplatelet therapy. To balance baseline characteristics between aspirin users and nonusers, investigators developed a propensity score-matched cohort. Researchers then estimated risk for HCC development.

Propensity score matching analysis generated 19,003 pairs. Median follow-up was 6.7 years.

Results showed the cumulative HCC incidence among patients who received aspirin was lower compared with nonusers of aspirin (P < .0001). Investigators also saw a correlation between aspirin use and lower risk for HCC (adjusted HR = 0.85; 95% CI, 0.78–0.92). Data showed a lower cumulative incidence of HCC in aspirin users without cirrhosis (16,507 pairs; aHR = 0.87 for HCC; 95% CI, 0.79–0.95).

“However, in patients with cirrhosis, there was no significant difference in the risk of HCC development between the aspirin treated group and the nontreated group,” Jang said.

Moreover, the correlation between aspirin therapy and HCC was not clearly evident (aHR = 1; 95% CI, 0.85–1.18).

StephenW

阿司匹林降低了慢性乙型肝炎的肝癌風險
添加到電子郵件通知

據《肝臟會議數字體驗》的一位主持人介紹，對於患有慢性乙型肝炎的患者，阿司匹林治療與降低肝細胞癌的風險有關。

首爾國立大學醫院內科和肝臟研究所的Heejoon Jang醫師在演講中說：“肝硬化對阿司匹林的使用與HCC發生風險之間的關聯有重大影響。”
阿司匹林

對於患有慢性乙型肝炎的患者，阿司匹林治療與降低肝細胞癌的風險相關。

Adobe股票

利用韓國國民健康保險數據庫，Jang及其同事確定了329,635名成年慢性乙型肝炎患者。其中有20,200人連續90天或更長時間接受阿司匹林治療，還有309,435人從未接受抗血小板治療。為了平衡阿司匹林使用者和非使用者之間的基線特徵，研究人員開發了一個傾向得分匹配的隊列。然後研究人員估算出肝癌發展的風險。

傾向得分匹配分析生成了19,003對。中位隨訪時間為6。7年。

結果顯示，接受阿司匹林治療的患者的累積肝癌發生率低於未服用阿司匹林的患者（P <.0001）。研究人員還發現阿司匹林的使用與較低的HCC風險之間存在相關性（校正後的HR = 0.85； 95％CI為0.78-0.92）。數據顯示，沒有肝硬化的阿司匹林使用者肝癌的累積發生率較低（16,507對；肝癌的aHR = 0.87； 95％CI，0.79–0.95）。

“但是，在肝硬化患者中，阿司匹林治療組與未治療組之間的肝癌發生風險沒有顯著差異，” Jang說。

此外，阿司匹林治療與肝癌之間的相關性尚不清楚（aHR = 1； 95％CI，0.85-1.18）。